|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03).
|
15294875 |
2004 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination.
|
24522186 |
2014 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To accomplish this, we first carried out an in silico analysis of RNA-seq databases and found that the distribution of alternative splicing isoforms of genes RPL13, HSP90B1, ENO1, EPDR1 and ZNF518B was altered in human CRC cell lines carrying the G13D KRAS mutation when compared to cell lines carrying wild-type KRAS.
|
27805251 |
2016 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The addition of cetuximab to first-line chemotherapy seems to benefit patients with KRAS G13D-mutant tumors.
|
22734028 |
2012 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared to patients with c.38G > A (rs112445441, p.G13D), patients with c.*4066delA (rs560890523) and c.38G > A (rs112445441, p.G13D) presented more aggressive tumors with highly invasive features.
|
27256640 |
2017 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D).
|
18098337 |
2008 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
In patients with G13D-mutated chemotherapy-refractory mCRC, there was no statistically significant improvement in disease control at 6 months with either cetuximab monotherapy or cetuximab plus irinotecan.
|
27114605 |
2016 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
This meta-analysis demonstrates no significant difference between KRAS G13D and other KRAS MT tumours in terms of treatment benefit from anti-EGFR mAbs for mCRC.
|
26812186 |
2016 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations.
|
22972628 |
2013 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
|
22734028 |
2012 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
|
27878354 |
2017 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
ICECREAM is a randomised, phase II, open-label, controlled trial comparing the efficacy of cetuximab alone or with irinotecan in patients with "quadruple wild type" or G13D-mutated metastatic colorectal cancer, whose disease has progressed on, or who are intolerant of oxaliplatin- and fluoropyrimidine-based chemotherapy.
|
27246726 |
2016 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
|
22537608 |
2012 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
This retrospective pooled analysis suggests comparable efficacy of cetuximab-based and bevacizumab-based first-line therapy in patients with p.G13D mutant mCRC.
|
22441566 |
2012 |
|
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
Furthermore, EGF‑ETA was just as potent in HCT116 (KRAS G13D) and SW480 (KRAS G12V) colon cancer cell lines harbouring KRAS hyperactivating mutations when compared to KRAS wild‑type HT29 colon cancer cells.
|
30226622 |
2018 |
|
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
The GR/RR IRS1 genotypes were associated with an increased risk of colon cancers with the KRAS2 G12D mutation (OR 2.3, 95% CI 1.5, 3.5 versus controls, OR 1.7, 95% CI 1.1, 2.6 versus KRAS2 wild type), the "no 192" IGFI genotype increased the risk of the KRAS2 G13D mutation (OR 2.3, 95% CI 1.2, 4.2 versus controls, OR 2.1, 95% CI 1.1, 4.0 versus wild type), and the DD IRS2 genotype increased the risk of the G12V KRAS2 mutation (OR 1.8, 95% CI 0.9, 3.5 versus controls, OR 2.0, 95% CI 1.0, 4.0 versus wild type).
|
16448675 |
2006 |
|
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations.
|
29498789 |
2018 |
|
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
|
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
Here we report a colon cancer case carrying a novel combination of K-RAS mutations involving codon 13 (Gly to Asp) and codon 19 (Leu to Phe), on separate alleles.
|
25675084 |
2015 |
|
Colon Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Furthermore, EGF‑ETA was just as potent in HCT116 (KRAS G13D) and SW480 (KRAS G12V) colon cancer cell lines harbouring KRAS hyperactivating mutations when compared to KRAS wild‑type HT29 colon cancer cells.
|
30226622 |
2018 |
|
Colon Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |